Off-label usage of immune checkpoint inhibitors in a cancer hospital
Objective To explore the off-label use and management points of immune checkpoint inhibitors(ICIs)in a cancer hospital,providing a reference for rational clinical drug use.Methods A retrospective investigation was conducted on the usage profile and off-label medication use of ICIs in a cancer hospital from January to June 2023.Analyse,evaluate and summarise the evidence base for off-label drug use with reference to high-level evidence-based medical evidence.Results Totally 527 patients were treated with 15 ICIs,involving 16 tumor types,and 16.88％(89/527)of them had the off-label drug use.Among them,the top three tumor type were cervical cancer(50.56％),hepatocellular carcinoma(13.48％),and nasopharyngeal carcinoma(10.11％),and the top three ICIs were tislelizumab(26.97％),camrelizumab(16.85％),and zimberelimab(15.73％).Conclusion All cases of off-label usage are supported by high-level evidence-based medical evidence.Standardised management of off-label usage can promote rational clinical use of medication.As drug label and guidelines are updated constantly,pharmacists should keep abreast of the research frontiers and pay attention to the evidence-based medical evidence simultaneously,so as to guarantee for the safe and effective use of medication.
NETL
NSTL
万方数据
